More on ARQT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (8.2 Score)
- FDA

Upcoming Events

- Earnings (8/6/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Arcutis Biotherapeutics (NQ:ARQT)
Delayed: 24.00 +0.03 (0.13%)
Prev. Close $23.97  
Open$23.57 
52 Wk High$ 
52 Wk Low$ 
Day High$24.09 
Day Low$23.25 
P/E N/A  
EPS$ 
Volume1,113,170 

Friends, Peers and Foes (?): MIRM, NAMS, TARS, PVLA, AMGN (more...)

Mar 5, 2026 09:01 AM Arcutis promotes Mas Matsuda to chief legal officer
Mar 5, 2026 09:01 AM Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Mar 4, 2026 04:18 PM Form 4 Arcutis Biotherapeutics, For: Mar 02 Filed by: Leonard Keith R
Mar 4, 2026 04:17 PM Form 4 Arcutis Biotherapeutics, For: Mar 02 Filed by: Welgus Howard G.
Mar 3, 2026 08:43 PM Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Edwards Larry Todd
Mar 3, 2026 08:43 PM Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Watanabe Todd
Mar 3, 2026 08:42 PM Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Matsuda Masaru
Mar 3, 2026 08:42 PM Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Vairavan Latha
Mar 3, 2026 08:42 PM Form 4 Arcutis Biotherapeutics, For: Aug 18 Filed by: Burnett Patrick
Mar 3, 2026 08:00 AM Arcutis starts phase 1 study of ARQ-234 for atopic dermatitis
View All Articles

Entities mentioned with ARQT

View All Entities